Private infusion care for high-cost biologic medicines: Investigating the implications for the public healthcare system

高成本生物药品的私人输液护理：调查对公共医疗保健系统的影响

• 批准号: 467969
• 负责人: Grundy Quinn
• 金额: $ 22.29万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-09-01 至 2025-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=467969&lang=en
• 关键词: Biologics/Biosimilars; High-Cost Medicines; Pharmaceutical Industry; Pharmaceutical Policy; Privatization; Qualitative Methods

Biologic medicines, among the most expensive medications ever sold in Canada, require administration by intravenous (IV) infusion every 6-8 weeks. To encourage their use, pharmaceutical companies set up a network of private infusion outpatient clinics whe

生物药物是加拿大有史以来销售的最昂贵的药物之一，需要每6-8周通过静脉（IV）输注给药。为了鼓励他们的使用，制药公司建立了一个私人输液门诊网络，